HUTCHMED (China) (HMDCF) Cash from Investing Activities (2018 - 2021)
HUTCHMED (China)'s (HMDCF) quarterly Cash from Investing Activities came in at -$315.9 million in Q2 2021, down 665.3% year-over-year from $55.9 million in Q2 2020, and down 297.41% quarter-over-quarter from $160.0 million in Q1 2021.
Analysis
HUTCHMED (China) (HMDCF) Cash from Investing Activities (2018 - 2021) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Cash from Investing Activities for 4 consecutive years, with -$315.9 million the latest figure, recorded in Q2 2021.
- On a quarterly basis, Cash from Investing Activities fell 665.3% year-over-year to -$315.9 million in Q2 2021; TTM through Jun 2021 was -$295.0 million, a 281.98% decrease from a year earlier, with the FY2025 full-year figure at -$29.4 million, up 69.38% from the prior year.
- Cash from Investing Activities was -$315.9 million for Q2 2021 at HUTCHMED (China), down from $160.0 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $160.0 million in Q1 2021 and troughed at -$315.9 million in Q2 2021.
- A 4-year average of -$11.0 million and a median of $19.0 million in 2019 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities jumped 299.29% in 2019 and plunged 665.3% in 2021, its largest moves.
- Over 4 years, Cash from Investing Activities stood at -$15.3 million in 2018, then surged by 193.2% to $14.2 million in 2019, then slumped by 390.3% to -$41.3 million in 2020, then sank by 665.3% to -$315.9 million in 2021.
- The last three Cash from Investing Activities figures came in at -$315.9 million (Q2 2021), $160.0 million (Q1 2021), and -$41.3 million (Q2 2020), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.37 Bn | 197.38 Bn | 7.24 Bn | -569.00 Mn |
| 2 | Gilead Sciences | 181.12 Bn | 177.94 Bn | 6.22 Bn | -10.35 Bn |
| 3 | Vertex Pharmaceuticals | 132.11 Bn | 124.26 Bn | 2.84 Bn | -45.80 Mn |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn | -92.70 Mn |
| 5 | Argenx Se | 61.69 Bn | 56.50 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.62 Bn | 49.48 Bn | 52.00 Mn | 329.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.14 Bn | 30.84 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn | -3.84 Bn |
| 9 | Roivant Sciences | 30.09 Bn | 30.09 Bn | 1.16 Mn | 281.26 Mn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2021 | -315.92 Mn |
| Mar 31, 2021 | 160.04 Mn |
| Jun 30, 2020 | -41.28 Mn |
| Mar 31, 2020 | -97.84 Mn |
| Dec 31, 2019 | 14.22 Mn |
| Sep 30, 2019 | 47.67 Mn |
| Jun 30, 2019 | 23.76 Mn |
| Mar 31, 2019 | 33.38 Mn |
| Dec 31, 2018 | -15.26 Mn |
| Sep 30, 2018 | 43.22 Mn |
| Jun 30, 2018 | -11.92 Mn |
| Mar 31, 2018 | 27.71 Mn |